TD Asset Management Inc Sells 9,590 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

TD Asset Management Inc lowered its stake in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 3.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 286,264 shares of the company's stock after selling 9,590 shares during the quarter. TD Asset Management Inc owned about 0.57% of Immunocore worth $8,983,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. bought a new stake in Immunocore during the first quarter worth approximately $225,000. Checkpoint Capital L.P. bought a new stake in Immunocore during the first quarter worth approximately $267,000. Banque Transatlantique SA bought a new stake in Immunocore during the first quarter worth approximately $278,000. Tema Etfs LLC boosted its position in Immunocore by 37.8% during the first quarter. Tema Etfs LLC now owns 15,428 shares of the company's stock worth $458,000 after purchasing an additional 4,234 shares during the period. Finally, Persistent Asset Partners Ltd bought a new stake in Immunocore during the first quarter worth approximately $663,000. Institutional investors own 84.50% of the company's stock.

Immunocore Stock Performance

Shares of NASDAQ IMCR opened at $33.56 on Monday. The business has a fifty day simple moving average of $33.78 and a 200 day simple moving average of $32.58. The company has a current ratio of 5.89, a quick ratio of 5.86 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -83.90 and a beta of 0.79. Immunocore Holdings PLC Sponsored ADR has a one year low of $23.15 and a one year high of $39.33.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. The business had revenue of $130.65 million during the quarter, compared to analyst estimates of $122.96 million. Immunocore had a negative return on equity of 5.40% and a negative net margin of 5.70%.Immunocore's revenue was up 30.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.23) earnings per share. Sell-side analysts expect that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Wall Street Zen lowered Immunocore from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Immunocore in a report on Wednesday, October 8th. Guggenheim assumed coverage on Immunocore in a report on Thursday, September 18th. They set a "neutral" rating for the company. Zacks Research lowered Immunocore from a "strong-buy" rating to a "hold" rating in a report on Thursday, September 4th. Finally, Jefferies Financial Group assumed coverage on Immunocore in a report on Monday, August 25th. They set a "buy" rating and a $48.00 price target for the company. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $56.89.

Insider Activity at Immunocore

In related news, insider David M. Berman sold 22,532 shares of the company's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $35.67, for a total value of $803,716.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 10.40% of the company's stock.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.